Irrevocable Beneficiary

In insurance, an irrevocable beneficiary is a beneficiary who has been designated to receive the proceeds of an insurance policy and whose rights to receive those proceeds cannot be changed without their consent.

Here are some key features of an irrevocable beneficiary:

• The policy owner cannot change the beneficiary designation without the consent of the irrevocable beneficiary.

• The irrevocable beneficiary has a vested interest in the policy and its proceeds.

• The policy owner retains all other rights and privileges related to the policy, such as the right to borrow against the policy or to change the premium payment schedule.

• The designation of an irrevocable beneficiary may have tax implications for the policy owner and the beneficiary.

For example, let's say John purchases a life insurance policy and designates his wife Jane as the irrevocable beneficiary. This means that John cannot change the beneficiary designation to someone else without Jane's consent. If John were to pass away, the insurance company would pay the death benefit directly to Jane, regardless of any changes that John may have wanted to make to the beneficiary designation. Jane would have a vested interest in the policy and its proceeds, and John would not be able to make any changes to that designation without her consent.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.